Successful treatment of recurrent small cell carcinoma of urinary bladder with pembrolizumab

IJU Case Reports

article

Tomoya Hatayama¹  Tetsutaro Hayashi²  Shinji Matsuzaki¹  Hiroshi Masumoto¹  Hiroyuki Yanai³  Hamidreza Abdi⁴  Jun Teishima²  Yasuhisa Hasegawa¹ 

[1] Department of Urology, National Hospital Organization Fukuyama Medical Center;Department of Urology, Hiroshima University Hospital;Department of Pathology, Okayama University Hospital;Department of Surgery, Division of Urology, University of Ottawa

关键词: bladder cancer;    immune checkpoint inhibitor;    immunotherapy;    small cell carcinoma of urinary bladder;    urothelial carcinoma;   

DOI  :  10.1002/iju5.12208

学科分类：社会科学、人文和艺术（综合）

来源: Wiley

【 摘 要 】

Introduction Small cell carcinoma of urinary bladder is rare and has an aggressive malignant behavior and poor prognosis. Advanced bladder cancers are treated with immune checkpoint inhibitors, however, its efficacy for small cell carcinoma of urinary bladder is unclear. Case presentation A 54-year-old female, diagnosed with clinical stage T2N0M0 small cell carcinoma of urinary bladder, underwent radical cystectomy after three cycles of etoposide-cisplatin neoadjuvant chemotherapy. Despite the fact that pathological examination revealed no residual carcinoma in bladder in her cystectomy specimen, local recurrence of a 60-mm mass detected in the follow-up investigation 7.5 months later. This was completely treated by pembrolizumab without any adverse effects. Immunohistochemical staining revealed that the tumor had no programmed death ligand 1 expression but it showed CD8-positive T-lymphocyte infiltration into the tumor. Conclusion Immune checkpoint inhibitors might have curative potentials for treatment of small cell carcinoma of urinary bladder.

【 授权许可】

CC BY|CC BY-NC|CC BY-NC-ND